List of Figures
1.2 List of Figures
Figure 1: Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections 9
Figure 2: Number of Products under Development by Companies, Respiratory Syncytial Virus (RSV) Infections 10
Figure 3: Number of Products under Development by Universities/Institutes, Respiratory Syncytial Virus (RSV) Infections 13
Figure 4: Number of Products under Development for Human Parainfluenza Virus 3 Infections 22
Figure 5: Number of Products under Development by Companies, Human Parainfluenza Virus 3 Infections 23
Figure 6: Number of Products by Top 10 Targets, Respiratory Syncytial Virus (RSV) Infections 25
Figure 7: Number of Products by Stage and Top 10 Targets, Respiratory Syncytial Virus (RSV) Infections 25
Figure 8: Number of Products by Top 10 Mechanism of Actions, Respiratory Syncytial Virus (RSV) Infections 26
Figure 9: Number of Products by Stage and Top 10 Mechanism of Actions, Respiratory Syncytial Virus (RSV) Infections 27
Figure 10: Number of Products by Routes of Administration, Respiratory Syncytial Virus (RSV) Infections 28
Figure 11: Number of Products by Stage and Routes of Administration, Respiratory Syncytial Virus (RSV) Infections 28
Figure 12: Number of Products by Top 10 Molecule Types, Respiratory Syncytial Virus (RSV) Infections 29
Figure 13: Number of Products by Stage and Top 10 Molecule Types, Respiratory Syncytial Virus (RSV) Infections 30
Figure 14: Number of Products by Targets, Human Parainfluenza Virus 3 Infections 31
Figure 15: Number of Products by Stage and Targets, Human Parainfluenza Virus 3 Infections 32
Figure 16: Number of Products by Mechanism of Actions, Human Parainfluenza Virus 3 Infections 33
Figure 17: Number of Products by Stage and Mechanism of Actions, Human Parainfluenza Virus 3 Infections 33
Figure 18: Number of Products by Top 10 Routes of Administration, Human Parainfluenza Virus 3 Infections 35
Figure 19: Number of Products by Stage and Routes of Administration, Human Parainfluenza Virus 3 Infections 35
Figure 20: Number of Products by Molecule Types, Human Parainfluenza Virus 3 Infections 36
Figure 21: Number of Products by Stage and Molecule Types, Human Parainfluenza Virus 3 Infections 37

 

List of Tables
1.1 List of Tables
Table 1: Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections 9
Table 2: Number of Products under Development by Companies, Respiratory Syncytial Virus (RSV) Infections 11
Table 3: Number of Products under Development by Universities/Institutes, Respiratory Syncytial Virus (RSV) Infections 14
Table 4: Products under Development by Companies, Respiratory Syncytial Virus (RSV) Infections 15
Table 5: Products under Development by Universities/Institutes, Respiratory Syncytial Virus (RSV) Infections 20
Table 6: Number of Products under Development for Human Parainfluenza Virus 3 Infections 22
Table 7: Number of Products under Development by Companies, Human Parainfluenza Virus 3 Infections 23
Table 8: Number of Products under Development by Universities/Institutes, Human Parainfluenza Virus 3 Infections 24
Table 9: Products under Development by Companies, Human Parainfluenza Virus 3 Infections 24
Table 10: Products under Development by Universities/Institutes, Human Parainfluenza Virus 3 Infections 24
Table 11: Number of Products by Stage and Target, Respiratory Syncytial Virus (RSV) Infections 26
Table 12: Number of Products by Stage and Mechanism of Action, Respiratory Syncytial Virus (RSV) Infections 27
Table 13: Number of Products by Stage and Route of Administration, Respiratory Syncytial Virus (RSV) Infections 29
Table 14: Number of Products by Stage and Molecule Type, Respiratory Syncytial Virus (RSV) Infections 31
Table 15: Number of Products by Stage and Target, Human Parainfluenza Virus 3 Infections 32
Table 16: Number of Products by Stage and Mechanism of Action, Human Parainfluenza Virus 3 Infections 34
Table 17: Number of Products by Stage and Route of Administration, Human Parainfluenza Virus 3 Infections 36
Table 18: Number of Products by Stage and Molecule Type, Human Parainfluenza Virus 3 Infections 37
Table 19: Respiratory Syncytial Virus (RSV) Infections – Pipeline by 3-V Biosciences Inc, 38
Table 20: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Abivax SA 38
Table 21: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Ablynx NV 39
Table 22: Respiratory Syncytial Virus (RSV) Infections – Pipeline by ADMA Biologics Inc 39
Table 23: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Agilvax Inc 40
Table 24: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Amarillo Biosciences Inc 40
Table 25: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Anima Biotech Ltd 41
Table 26: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Aridis Pharmaceuticals LLC 41
Table 27: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Artificial Cell Technologies Inc 41
Table 28: Respiratory Syncytial Virus (RSV) Infections – Pipeline by AstraZeneca Plc 42
Table 29: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Bavarian Nordic A/S 43
Table 30: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Celltrion Inc 43
Table 31: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Curevac AG 44
Table 32: Respiratory Syncytial Virus (RSV) Infections – Pipeline by DBV Technologies SA 44
Table 33: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Enanta Pharmaceuticals Inc 45
Table 34: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Evec Inc 45
Table 35: Respiratory Syncytial Virus (RSV) Infections – Pipeline by F. Hoffmann-La Roche Ltd 46
Table 36: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Gene Techno Science Co Ltd 46
Table 37: Respiratory Syncytial Virus (RSV) Infections – Pipeline by GenVec Inc 47
Table 38: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Gilead Sciences Inc 47
Table 39: Respiratory Syncytial Virus (RSV) Infections – Pipeline by GlaxoSmithKline Plc 48
Table 40: Respiratory Syncytial Virus (RSV) Infections – Pipeline by iBio Inc 48
Table 41: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Immunovaccine Inc 49
Table 42: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Immunwork Inc 49
Table 43: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Inovio Pharmaceuticals Inc 50
Table 44: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Johnson & Johnson 51
Table 45: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Karyopharm Therapeutics Inc 51
Table 46: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Kineta Inc 52
Table 47: Respiratory Syncytial Virus (RSV) Infections – Pipeline by mAbxience SA 52
Table 48: Respiratory Syncytial Virus (RSV) Infections – Pipeline by MedImmune LLC 52
Table 49: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Medivir AB 53
Table 50: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Mymetics Corp 54
Table 51: Respiratory Syncytial Virus (RSV) Infections – Pipeline by NanoBio Corp 54
Table 52: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Navigen Inc 54
Table 53: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Novavax Inc 55
Table 54: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Phoenix Biotechnology Inc 55
Table 55: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Profectus BioSciences Inc 56
Table 56: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Pulmocide Ltd 56
Table 57: Respiratory Syncytial Virus (RSV) Infections – Pipeline by ReViral Ltd 57
Table 58: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Romark Laboratories LC 57
Table 59: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Takeda Pharmaceutical Co Ltd 58
Table 60: Respiratory Syncytial Virus (RSV) Infections – Pipeline by TechnoVax Inc 58
Table 61: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Themis Bioscience GmbH 58
Table 62: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Vault Pharma Inc 59
Table 63: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Vaxart Inc 59
Table 64: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Virometix AG 60
Table 65: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Visterra Inc 60
Table 66: Respiratory Syncytial Virus (RSV) Infections – Pipeline by VLP Biotech Inc 60
Table 67: Human Parainfluenza Virus 3 Infections – Pipeline by 3-V Biosciences Inc 61
Table 68: Human Parainfluenza Virus 3 Infections – Pipeline by Amarillo Biosciences Inc 61
Table 69: Human Parainfluenza Virus 3 Infections – Pipeline by Ansun Biopharma Inc 62
Table 70: Human Parainfluenza Virus 3 Infections – Pipeline by Moderna Therapeutics Inc 62
Table 71: Respiratory Syncytial Virus (RSV) Infections – Dormant Projects 63
Table 72: Human Parainfluenza Virus 3 Infections – Dormant Projects 67
Table 73: Respiratory Syncytial Virus (RSV) Infections – Discontinued Products 68
Table 74: Human Parainfluenza Virus 3 Infections – Discontinued Products 68